Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience

BMC Gastroenterology

Research Article

Renan Spode¹  Nicolas Glaser¹  Christoph Neumann-Haefelin¹  Tobias Boettler¹  Nico Buettner¹  Michael Schultheiss¹  Robert Thimme¹  Dominik Bettinger²  Eleni Gkika³  Thomas Baptist Brunner³  Lars Maruschke⁴ 

[1] Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, D-79106, Freiburg, Germany;Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, D-79106, Freiburg, Germany;Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany;Department of Radiation Oncology, Medical Center University of Freiburg,Faculty of Medicine, University of Freiburg, Robert-Koch-Str. 3, D-79106, Freiburg, Germany;Department of Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, D-79106, Freiburg, Germany;

关键词: Hepatocellular carcinoma;    Metastases;    Sorafenib;    Transarterial chemoembolization;    Prognosis;   

DOI  :  10.1186/s12876-017-0656-z

 received in 2017-05-17, accepted in 2017-08-01,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundAs prognosis of patients with metastatic hepatocellular carcinoma (HCC) is mainly determined by intrahepatic HCC progression, local treatment with TACE may result in improved OS, although it is not recommended. The purpose of this study was to analyze retrospectively the efficacy of TACE and its impact on OS in patients with metastatic hepatocellular carcinoma (HCC).MethodsTwo hundred and fifteen patients with metastatic HCC who were treated at our Liver Center between 2003 and 2014 were included in this retrospective analysis. Medical records, laboratory parameters and imaging studies were analyzed. Treatment of metastatic HCC and OS were assessedResultsOne hundred and two patients (47.4%) did not receive any HCC specific treatment while 48 patients (22.3%) were treated with sorafenib, 42 patients (19.5%) with TACE and 23 patients (10.7%) received treatment with TACE and sorafenib in combination. Survival analyses and Cox regression models revealed that TACE and a combination therapy of TACE and sorafenib were significant prognostic factors in metastatic HCC. However, further analyses revealed that there was no additional prognostic effect of adding sorafenib to TACE treatment in this patient cohort.ConclusionsIn metastatic HCC, treatment of intrahepatic tumor by TACE may be associated with improved survival. These results support the prognostic importance of treating intrahepatic HCC even in patients with metastatic disease. Therefore, we suggest evaluating the technical feasibility of TACE in all metastatic patients.

【 授权许可】

CC BY   
© The Author(s). 2017